Institute of Health and
Biomedical Innovation
a university for the real world

IHBI Advances

IHBI Advances is the quarterly newsletter from the QUT Institute of Health and Biomedical Innovation (IHBI). Each issue highlights research outcomes and profiles researchers as they seek better health in our lifetime through multidisciplinary research innovation.

September 2020: Edition 42

In this issue:

Subscribe to IHBI Advances news rss feed

People with concussion central to genomic research collaboration

10-09-2020 Headache or migraine following a traumatic brain injury (TBI) is common and can cause significant healthcare burden and drastically affect quality of life. There are few reliable indicators to suggest who will have specific or long-term effects from TBI. 

Evidence of shared genetics for endometriosis and migraine

10-09-2020 Comorbidity is the existence of two or more medical conditions simultaneously, regardless of whether one causes the other. Endometriosis and migraine co-occur in people more than expected by chance, but the cause and biological mechanisms underlying their comorbidity remain unknown.

Unique genetic mutations at the core of chronic disease research

10-09-2020 Life expectancy of Aboriginal people is much lower than other Australians, in part due to an apparent genetic predisposition to chronic diseases. IHBI research aims to better understand the genetics that cause the diseases to improve early detection and prevention strategies.

Technology and collaboration aid bowel disease studies

10-09-2020 Present treatments are unable to provide long-term remission for people with inflammatory bowel disease (IBD), allowing development of related diseases such as colorectal cancer and impacting quality of life. IHBI research uses genomics to improve IBD understanding and provide new treatment options.

Uncovering epigenetic changes linked to trauma and resilience

10-09-2020 Stress-related disorders are the single largest contributor to years lived in ill health and reduce the total years of healthy life for Australians. Why some people develop psychiatric disorders after experiencing a traumatic situation and others do not is a key question for IHBI researchers.

Personalised approach to limit adverse reactions to medicines

10-09-2020 Adverse reactions to medications are a major cause of disease and death globally. Genomics shows promise in personalising dosing and prescriptions, limiting side effects and maximising therapeutic efficacy.

Contacts

IHBI Communications

Subscribe to our newsletter

Stay up to date with IHBI's news, events and achievements by subscribing to our quarterly newsletter, IHBI Advances.